in-PharmaTechnologist.com presents its weekly round-up of the lates new appointments in the pharmaceutical world, including news from Capsugel, Shire and Savient.
Capsugel has appointed Donal Loughrey senior VP of operations and supply chain.
Loughrey will take charge of the capsule maker’s manufacturing, supply chain and quality.
Previously he was the head of regional technical operations in Asia Pacific for Sandoz.
Shire has named Frederic Chereau as senior VP for its human genetic therapies (HGT) business.
He will also take charge of the angioedema franchise.
Previously, Chereau was president and CEO of Pervasis Therapeutics, which was recently aqcquired by Shire.
Sylvie Gregoire, president of Shire HGT said: "With our recent strategic hires, we continue to strengthen our leadership team at HGT, and Frederic will support our goal of helping those with rare diseases lead better lives."
John Hamill has become senior VP and CFO for Savient Pharmaceuticals.
He joins the firm from PharmaNet, where he was chief financial officer.
Lou Ferrari, president and CEO said: “He will be responsible for all aspects of our financial functions and for ensuring the company meets its growth objectives in the most cost-effective manner through the implementation of financial and operational controls and the execution of the financial roadmap.”
Medigene AG has drafted Peter Llewellyn-Davies onto its board.
He joins the board after leaving Wilex - where he was CFO. He replaces Arnd Christ, who is leaving Medigene’s board as well as his role as CFO to pursue a “new professional challenge”.
Chairman of Medigene’s supervisory board, Ernst-Ludwig Winnacker, said: "I would like to thank Mr Christ for the excellent work he has carried out over the last two-and-a-half years since he became CFO and wish him all the best in his future endeavours.”
CEO Frank Mathias also said that Llewellyn-Davies’ appointment brings some biotech experience to the board, which he said was important for its next phase of growth.
Emisphere Technologies has appointed Alan Rubino as its new president and CEO.
Formerly the CEO and president of New American Therapeutics, Rubino said of his new appointment: "I was attracted to Emisphere by the broad potential of its Eligen(R) Technology to improve therapeutic delivery of vital pharmaceutical products.”
Chairman Timothy Rothwell added that the company will soon commercialise its first product – Eligen(R) Oral B12 – and that Rubino’s appointment will help drive the process.
TiGenix has namedformer GSK execs Jean Stéphenne and Russell Greig as independent directors. Stéphenne will be chairman.
The pair replace Koenraad Debackere and Mounia Chaoui-Roulleau, who both recently resigned from the board.
"Their long and broad experience with all aspects of drug development and building innovative pharmaceutical and biotechnology companies will be of immense value as TiGenix enters into a pivotal phase of its growth with the commercial roll-out of ChondroCelect and the advanced clinical development of its cell therapy programs,” said Willy Duron, who steps down as chairman to become a board member.